TME Pharma

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned. 

SNO 2023 poster: Lastest data in Glioblastoma from the expansion arm with NOX-A12 + radiotherapy + anti-VEGF

Fact SheetCorporate Presentation

Press Release 2024, April 25 06:00 p.m. TME Pharma publishes 2023 financial results and provides operating update 2024, April 23 08:00 a.m. TME Pharma announces 33% of patients receiving NOX-A12 in combination with bevacizumab and radiotherapy achieve two-year survival in GLORIA Phase 1/2 trial in brain cancer 2024, April 02 08:00 p.m. TME Pharma receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer

Events LSX World Congress Aram Mangasarian, Ewelina Staniuk April 29 – 30 | London, UK Bio International Convention Dirk Eulberg, Ewelina Staniuk June 3 – 6 | San Diego, CA